SCHEMBL10036083

SCHEMBL10036083

CCN1C(=O)/C(=C\C=C2/Oc3ccccc3N2CC)OC1=S

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 14/20 0.59
▸ KMT2A Q03164 14/20 0.59
▸ MAPT P10636 8/20 0.59
▸ ALDH1A1 P00352 6/20 0.59
▸ MAPK1 P28482 5/20 0.59
▸ HTT P42858 1/20 0.59
▸ TDP1 Q9NUW8 2/20 0.53
▸ TNNI3 P19429 1/20 0.53
▸ TNNT2 P45379 1/20 0.53
▸ TNNC1 P63316 1/20 0.53
▸ ALOX15 P16050 1/20 0.50
▸ HPGD P15428 1/20 0.46
▸ NPC1 O15118 4/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ IDE P14735 1/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ THRB P10828 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8607857 1.00 MEN1 (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL8358074 0.88 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL14848959 0.82 ALDH1A1 (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13751809 0.82 ALDH1A1 (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL22906177 0.81 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036037 0.81 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9194239 0.80 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036014 0.80 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9194237 0.80 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036043 0.79 MAPT (0.59) MEN1KMT2AMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback